Scarica l'app Stockscreener
2.45
1.24%
0.03
Dopo l'orario di chiusura:
2.41
-0.04
-1.63%
Lipocine Inc Borsa (LPCN) Ultime notizie
Lipocine Inc (NASDAQ: LPCN) Share Price, LPCN Stock News, LPCN Share Price & Updates - Kalkine
Lipocine (LPCN) Advances 3.06% to $2.35, Testing Key Resistance ZoneSeasonality Effect - vinanet.vn
Lipocine (LPCN) Jumps 5.35% to $2.27 as Buyers Target $2.38 ResistanceTRIN Signal - vinanet.vn
Lipocine (LPCN) Q2 2026 Results: The Bottom-Line Figure Beats Its Comparison for the Current Session; After Results: The Share Price Moves Only Slightly under the Current SnapshotGross Profit Margin - vinanet.vn
Lipocine (LPCN) adds Grissinger to pay panel at $7,500 a year - Stock Titan
Lipocine (LPCN) Q2 2026 Scorecard: EPS Comes in Above Forecast in Latest Trading; Price Reaction - vinanet.vn
Lipocine (LPCN) Q2 2026 Filing Snapshot: Reported EPS Tops Expectations in Latest Trading; Immediate Response: The Stock Ends Down 0.49% in the Current UpdateEarnings Preview - dars.gov.et
Lipocine Inc. (LPCN) Edges Higher to $2.12, Holding Above Key SupportAdvance Decline Volume - dars.gov.et
Lipocine Stock Price Forecast. Should You Buy LPCN? - StockInvest.us
Lipocine (LPCN): Squadron funds report 810,000 shares, a 9.8% ownership stake - Stock Titan
LPCN Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Consensus as Revenue Remains Absent - Vinanet
Weekly Recap: Q2 revenue drop and Brilzio partner search - TradingView
LPCN Q2 2026 Earnings: Loss Narrower Than Expected, Shares Ease 1.41%Earnings Turnaround - vinanet.vn
Lipocine Inc. (NASDAQ: LPCN) awards director 2,000 stock options - Stock Titan
Lipocine Inc. (LPCN) director Grissinger files initial ownership statement - Stock Titan
Lipocine Inc (LPCN) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
Lipocine files Form 3 initial beneficial ownership statement for director Michael Grissinger - Bitget
Lipocine Inc (LPCN) Stock News Today - TradingKey
LPCN Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage SpendingMargin Improvement Report - vinanet.vn
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Lipocine (LPCN) and High Tide (HITI) - The Globe and Mail
Lipocine (LPCN) Slips 1.8% to $2.13 as Biotech Stock Holds Above Key $2.02 SupportVWAP Breakout - dars.gov.et
A. G. P. Maintains Lipocine(LPCN.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Lipocine Q2 2026 earnings: Missing license revenue drives top-line decline - TradingKey
Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 - Morningstar
Lipocine Q2 net loss widens as revenue declines - TradingView
Lipocine posts $2.6 million Q2 net loss as revenue falls - Quiver Quantitative
Lipocine Inc. Q2 2026: Revenue $190099 EPS $(0.32) — 10-Q Summary - TradingView
Lipocine (NASDAQ: LPCN) widens H1 loss but extends cash runway to 2027 - stocktitan.net
Lipocine reports Q2 2026 loss, updates on postp... - Pluang
Lipocine Appoints Michael J. Grissinger to Board of Directors - Morningstar
Lipocine Appoints Industry Veteran Grissinger to Board - TipRanks
Lipocine appoints Michael Grissinger to board of directors By Investing.com - Investing.com Australia
Lipocine appoints Michael Grissinger to board of directors - Investing.com India
Lipocine Inc. Announces Appointment of Michael J. Grissinger to Board of Directors, Effective August 3, 2026 - marketscreener.com
Lipocine Inc expected to post a loss of 43 cents a shareEarnings Preview - TradingView
Lipocine Inc (LPCN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lipocine Inc (LPCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
LPCN|Lipocine Inc|Price:2.420|Chg%:+0.065 - TradingKey
Lipocine Inc (LPCN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lipocine Inc (LPCN) Income Statement - TradingKey
Lipocine Inc (LPCN) Balance Sheet - TradingKey
Lipocine Inc (LPCN) Cash Flow - TradingKey
Lipocine Inc. (LPCN) Q1 2026 Earnings: EPS Miss Pressures Shares as Pipeline Progress Remains KeyCost Structure Review - Vinanet
LPCN|Lipocine Inc|Price:2.080|Chg%:-0.110 - TradingKey
Lipocine Inc (LPCN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Lipocine Inc (LPCN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Lipocine Market Sentiment - Benzinga España
LPCN|Lipocine Inc|Price:2.210|Chg%:-0.020 - TradingKey
Lipocine Q1 2026 Earnings: Losses Slightly Wider Than Expected on No RevenueEPS Growth Report - dars.gov.et
LPCN Q1 2026 Earnings: Larger-than-Anticipated Loss as Development Spending ContinuesEPS Growth Rate - vinanet.vn
Lipocine (LPCN) Faces Slight Pullback Amid Sector VolatilityBear Pennant - dars.gov.et
Lipocine Inc. (LPCN) Holds Near Support After Modest Gain, Resistance in FocusBull Pennant - dars.gov.et
Lipocine Inc. (LPCN) Approaches Key Support After 2.85% Decline – Technical Levels in FocusFibonacci Arc - dars.gov.et
LPCN Q1 2026 Earnings: Wider-Than-Expected Loss Drags Shares LowerHealthcare Earnings Report - dars.gov.et
Form 4 Lipocine Inc For: 30 June By Investing.com - Investing.com Canada
Lipocine (LPCN) CEO Mahesh Patel receives 52,781 stock options grant - Stock Titan
LPCN Q1 2026 Earnings: Wider-Than-Expected Loss as Pipeline Progress Remains KeyProfit Inflection Point - dars.gov.et
Lipocine Inc. (LPCN) Narrows Slightly, Holds Within Key RangeVolatility Breakout Picks - dars.gov.et
Enterprise value to revenue forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
Price to book forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
Price to earnings forward of Lipocine Inc. – NASDAQ:LPCN - TradingView
0.86%
0.31%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):